for people ages 18-85 (full criteria)
at La Jolla, California and other locations
study started
estimated completion



The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

Official Title

A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction


Obstructive Hypertrophic Cardiomyopathy (oHCM), Obstructive Hypertrophic Cardiomyopathy, oHCM, CK-3773274, CK-274, Aficamten, SEQUOIA-HCM, CY 6031, SEQUOIA, Cardiomyopathies, Hypertrophic Cardiomyopathy, Hypertrophy, CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)


You can join if…

Open to people ages 18-85

  • Males and females between 18 and 85 years of age, inclusive, at screening.
  • Body mass index <35 kg/m2.
  • Diagnosed with HCM per the following criteria:
    • Has LV hypertrophy and non-dilated LV chamber in the absence of other cardiac disease and
    • Has an end-diastolic LV wall thickness as measured by the echocardiography core laboratory of:
      • ≥15 mm in one or more myocardial segments OR
      • ≥13 mm in one or more wall segments and a known-disease-causing gene mutation or positive family history of HCM
  • Has resting LVOT-G ≥30 mmHg and post-Valsalva LVOT G ≥50 mmHg during screening as determined by the echocardiography core laboratory.
  • LVEF ≥60% at screening as determined by the echocardiography core laboratory.
  • NYHA Functional Class II or III at screening.
  • Hemoglobin ≥10g/dL at screening.
  • Respiratory exchange ratio (RER) ≥1.05 and pVO2 ≤90% predicted on the screening CPET per the core laboratory.
  • Patients on beta-blockers, verapamil, diltiazem, or disopyramide should have been on stable doses for >6 weeks prior to randomization and anticipate remaining on the same medication regimen during the trial. Patients treated with disopyramide must also be concomitantly treated with a beta blocker and/or calcium channel blocker.

You CAN'T join if...

  • Known or suspected infiltrative, genetic or storage disorder causing cardiac hypertrophy that mimics oHCM (eg, Noonan syndrome, Fabry disease, amyloidosis).
  • Significant valvular heart disease (per investigator judgment).
    • Moderate-severe valvular aortic stenosis.
    • Moderate-severe mitral regurgitation not due to systolic anterior motion of the mitral valve.
  • History of LV systolic dysfunction (LVEF <45%) or stress cardiomyopathy at any time during their clinical course.
  • Inability to exercise on a treadmill or bicycle (eg, orthopedic limitations).
  • Has been treated with septal reduction therapy (surgical myectomy or percutaneous alcohol septal ablation) or has plans for either treatment during the trial period.
  • Documented paroxysmal atrial fibrillation during the screening period.
  • Paroxysmal or permanent atrial fibrillation is only excluded IF:
    • rhythm restoring treatment (eg, direct-current cardioversion, atrial fibrillation ablation procedure, or antiarrhythmic therapy) has been required ≤6 months prior to screening.
    • rate control and anticoagulation have not been achieved for at least 6 months prior to screening.
  • History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening.
  • Has received prior treatment with CK-3773274 or mavacamten.


  • UC San Diego Health - Sulpizio Cardiovascular Center
    La Jolla California 92037 United States
  • Cedars-Sinai Medical Center - Smidt Heart Institute Clinic
    Los Angeles California 90048 United States


in progress, not accepting new patients
Start Date
Completion Date
Phase 3 Cardiomyopathy Research Study
Study Type
About 282 people participating
Last Updated